Genes improperly granted patents

Some time mid last year six breast cancer patients sued reputed Myriad Genetics, a company that holds patent of two vital genes BRCA1 and BRCA2 that play a role in increasing the risk of breast and ovarian cancers. The fees that the company charges for these genetic tests is a whopping $3,000 which these women claim they cannot afford and the most important of all these women cannot get a second opinion regarding the tests since no one else does them.

In a recent development Judge Robert W Sweet said that these genes involved a "law of nature" and the patents had been "improperly granted." According to U.S. law, products of nature cannot be patented because they are pre-existing substances found in the wild.

This verdict can have serious consequences on biotechnology companies since nearly 20% of the genes in human body are already patented. In a direct reaction stocks of many such companies fell on Tuesday. The question is what will be the long term impact of such a ruling.

Judge Sweet however said in his 152 page ruling that this judgment will not affect the industry in a detrimental way. Some other legal heads concurred that the actual effects of this ruling will be felt years from now. The immediate effects will also be limited because of the decision made in a District court.

A Myriad spokesperson said that they would appeal on Tuesday with legal advisors feeling that they could overturn the ruling.

The Supreme Court right now is on the verge of giving judgment in the Bilski case. This case is about a dispute over a method of hedging risk in commodities trading. This case could give the Supreme Court a chance to set new standards on what is patentable.

“We are still waiting, holding our breath for the Bilski case,” said Kari Stefansson, head of research at DeCode Genetics, which sells disease risk tests similar to those sold by Myriad.

However geneticists say patents for genes could hamper competition in gene based application development, academic research, innovations and newer diagnostics apart from the cost issues.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Genes improperly granted patents. News-Medical. Retrieved on July 22, 2024 from

  • MLA

    Mandal, Ananya. "Genes improperly granted patents". News-Medical. 22 July 2024. <>.

  • Chicago

    Mandal, Ananya. "Genes improperly granted patents". News-Medical. (accessed July 22, 2024).

  • Harvard

    Mandal, Ananya. 2018. Genes improperly granted patents. News-Medical, viewed 22 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 and metallic taste: Study connects immunoglobulin levels to sensory impairment